An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
GlycoMimetics, Inc. (GLYC) will host a conference call and webcast to report first quarter 2024 financial results on May 9, 2024. Participants can access the call by phone or webcast. A replay will be available for 30 days.
GlycoMimetics, Inc. (GLYC) ospiterà una conferenza telefonica e un webcast per rendicontare i risultati finanziari del primo trimestre del 2024 il 9 maggio 2024. I partecipanti possono accedere alla chiamata telefonicamente o tramite webcast. Una registrazione sarà disponibile per 30 giorni.
GlycoMimetics, Inc. (GLYC) organizará una llamada de conferencia y una transmisión web para informar los resultados financieros del primer trimestre de 2024 el 9 de mayo de 2024. Los participantes podrán acceder a la llamada por teléfono o a través de la transmisión web. Estará disponible una repetición durante 30 días.
글리코미멤틱스(GlycoMimetics), Inc. (GLYC)는 2024년 5월 9일에 2024년 1분기 재무 결과를 보고하기 위한 컨퍼런스 콜과 웹캐스트를 개최할 예정입니다. 참가자는 전화 또는 웹캐스트를 통해 연결할 수 있습니다. 재생은 30일 동안 사용 가능합니다.
GlycoMimetics, Inc. (GLYC) organisera une conférence téléphonique et un webcast le 9 mai 2024 pour rapporter les résultats financiers du premier trimestre de 2024. Les participants pourront accéder à l'appel par téléphone ou via webcast. Une rediffusion sera disponible pendant 30 jours.
GlycoMimetics, Inc. (GLYC) wird am 9. Mai 2024 einen Konferenzanruf und Webcast abhalten, um die Finanzergebnisse für das erste Quartal 2024 vorzustellen. Teilnehmer können sich telefonisch oder per Webcast einwählen. Eine Wiedergabe ist 30 Tage lang verfügbar.
Positive
None.
Negative
None.
ROCKVILLE, Md.--(BUSINESS WIRE)--
GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET.
To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time.
A live webcast of the call will be available on the “Investors” tab on the GlycoMimetics website. A webcast replay will be available for 30 days following the call.
About GlycoMimetics, Inc.
GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company’s scientific approach is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform is being deployed to discover small molecule drugs, known as glycomimetics, that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. GlycoMimetics is leveraging its differentiated expertise with this scientific approach in order to advance its pipeline of wholly owned drug candidates. The company’s goal is to develop transformative therapies for diseases with high unmet medical need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
at glycomimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. glycomimetics is a clinical-stage biotechnology company. we use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. since the company’s inception in 2003, we have developed a robust, diversified product pipeline. we are a public company traded on the nasdaq under the symbol glyc.
